Phosphate metabolism sits quietly at the center of nearly every vital biological process — from ATP synthesis to bone mineralization to cell signaling — yet the molecular machinery responsible for shuttling phosphate into cells has remained structurally poorly understood. New structural insight into this gating system could eventually inform treatments for conditions ranging from pulmonary alveolar microlithiasis to chronic kidney disease, where phosphate dysregulation plays a central pathological role.
Using high-resolution cryo-electron microscopy, researchers resolved the three-dimensional structure of SLC34A2, a sodium-coupled phosphate transporter in the SLC34 family, at sufficient resolution to identify its distinct architectural features and proposed gating mechanism. Unlike structurally characterized members of related transporter families, SLC34A2 appears to adopt a unique conformational framework for coupling sodium electrochemical gradients to inorganic phosphate uptake. The structures captured multiple conformational states, providing a mechanistic window into how the transporter opens and closes access to the phosphate-binding site — a process critical for regulating intracellular phosphate concentrations across epithelial tissues in the lung, kidney, and intestine.
This work lands in a field that has long relied on indirect electrophysiological and biochemical inference to model SLC34 function, making direct structural resolution genuinely meaningful rather than incremental. SLC34A2 mutations are causally linked to pulmonary alveolar microlithiasis, a rare but serious lung condition characterized by calcium-phosphate microcrystal accumulation, and the transporter is also implicated in phosphate reabsorption relevant to chronic kidney disease progression. Understanding the precise gating mechanism opens rational drug-design pathways where none previously existed. That said, this is foundational structural biology — the leap from atomic-resolution models to clinical therapeutics remains long, and the work does not include functional validation in disease models. Still, for a transporter family this physiologically consequential, resolving its architecture represents a meaningful platform advance.